Renal Insufficiency Global Market Report 2025

The renal insufficiency market size has grown rapidly in recent years. It will grow from $10.87 billion in 2024 to $12.14 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period can be attributed to the rising cases of high blood pressure and diabetes, the increasing prevalence of chronic kidney disease (CKD), a higher occurrence of urinary tract obstructions, an aging population, and greater awareness and education about kidney health.

The renal insufficiency market size is expected to see rapid growth in the next few years. It will grow to $18.68 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to the rising prevalence of acute kidney injuries (AKI), increasing adoption of home-based treatment options, a surge in healthcare expenditure, and greater investments in research and development. Key trends include advancements in medical technology, innovations in treatment options, the integration of personalized medicine, improvements in dialysis technology, and the development of new and innovative medications.

The rising prevalence of high blood pressure and diabetes is expected to drive the growth of the renal insufficiency market in the coming years. These conditions are influenced by factors such as poor diet, lack of physical activity, obesity, genetic predisposition, and an aging population. High blood pressure damages kidney blood vessels by causing scarring and reducing filtration capacity, while diabetes leads to thickened and overworked kidney vessels due to elevated blood sugar levels. Both conditions accelerate kidney damage, ultimately resulting in renal insufficiency. For example, in May 2024, the National Health Service (NHS), a UK-based government agency, reported that the number of high blood pressure diagnoses in the South East increased by 71,120 patients in December 2023, marking a 5.4% rise compared to December 2022. Additionally, in April 2023, the British Diabetic Association, a UK-based charity organization, stated that 4.3 million people in the UK had been diagnosed with diabetes. Consequently, the increasing prevalence of high blood pressure and diabetes is fueling the expansion of the renal insufficiency market.

Leading companies in the renal insufficiency market are focusing on the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to address renal and cardiovascular complications in patients with diabetes and chronic kidney disease (CKD). These medications enhance glucose control, reduce inflammation, and lower oxidative stress in the kidneys, thereby slowing the progression of renal insufficiency. For example, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, received Food and Drug Administration (FDA) approval for Ozempic (semaglutide) to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD. This approval underscores the growing role of GLP-1 RAs in providing a dual approach to managing diabetes and renal insufficiency, addressing key unmet medical needs for patients with progressive CKD.

In February 2023, AstraZeneca PLC, a UK-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition enhances AstraZeneca’s cardiorenal portfolio by incorporating baxdrostat (CIN-107), an aldosterone synthase inhibitor designed to lower blood pressure in patients with treatment-resistant hypertension. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company focused on developing treatments for individuals with moderate to severe renal impairment or kidney failure.

Major players in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, and Sorin Group.

North America was the largest region in the renal insufficiency market in 2024. The regions covered in renal insufficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the renal insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Renal insufficiency refers to the decreased ability of the kidneys to filter waste products and maintain fluid and electrolyte balance in the body. It can result from chronic conditions such as diabetes, hypertension, or acute kidney injury, leading to toxin buildup in the blood. If left untreated, renal insufficiency may progress to chronic kidney disease (CKD) or kidney failure, necessitating dialysis or transplantation.

The primary treatment options for renal insufficiency include medications, dialysis, kidney transplantation, and other interventions. Medications help manage symptoms, slow disease progression, and address complications such as high blood pressure, diabetes, and anemia. The condition progresses through different stages, including chronic kidney disease (CKD) stages and end-stage renal disease (ESRD). Treatment is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users including dialysis centers, hospitals, clinics, and research and academic institutes.

The renal insufficiency market research report is one of a series of new reports that provides renal insufficiency market statistics, including renal insufficiency industry global market size, regional shares, competitors with a renal insufficiency market share, detailed renal insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the renal insufficiency industry. This renal insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The renal insufficiency market consists of sales of dialysis equipment, renal replacement therapies, kidney transplantation services, and pharmaceutical treatments for managing kidney function. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.